• PI Nanoliposomes and Cellular Immunity

  2026-10-13

  A source-grounded editorial overview of a 2026 Journal of Controlled Release study proposing phosphatidylinositol-based nanoliposomes as self-adjuvanting, endoplasmic-reticulum-targeting vaccine carriers. The reported mouse findings suggest stronger CD8 T-cell responses and tumor control than MF59-adjuvanted ovalbumin, while the supplied evidence remains limited by its condensed, pre-proof format and lack of detailed quantitative results.

• Hoechst 33258 in KRas Tumor Mechanobiology

  2026-10-13

  A source-grounded overview of Hoechst 33258 as a DNA-imaging reagent and of reported links between KRas transfer, tunneling nanotubes, and tumor-cell mechanics. The evidence supports a mechanistic hypothesis in cell-based models, but does not establish clinical utility or prove that membrane mechanics alone drive metastasis.

• 7-dehydro Cholesterol and Antiviral Fish Biology

  2026-10-12

  A 2026 Aquaculture Reports study identified dhcr7 as a candidate genetic determinant of grass carp resistance to GCRV-II. The findings connect cholesterol biosynthesis with antiviral immunity in vivo, while leaving important questions about mechanism, long-term fitness, strain breadth and applicability beyond the studied fish model.

• Cisapride and Deep-Learning Cardiotoxicity Evidence

  2026-10-12

  An evidence-bounded overview of Grafton et al.’s iPSC-cardiomyocyte screen, its reported cardiotoxicity signals, and what the study does—and does not—show about Cisapride (R 51619).

• Drug Response Metrics in Cancer Cell Models

  2026-10-10

  Hannah R. Schwartz’s 2022 dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a framework that separates growth inhibition from cell killing and emphasizes their different proportions and timing, improving interpretation of in vitro drug-response studies.

• Lactylation–NSUN2 Axis Drives Pancreatic Cancer PNI

  2026-10-09

  A 2026 Theranostics study identifies NSUN2 K692 lactylation as a mechanistic link between lactate accumulation, RNA m5C modification, and perineural invasion in pancreatic ductal adenocarcinoma. Its multi-level evidence supports a lactate–NSUN2–m5C–CDCP1/STC1 axis, while the findings remain primarily preclinical and require further validation in clinically representative cohorts and therapeutic studies.

• Calcitriol and VDR Signaling: Research Evidence

  2026-10-09

  Calcitriol, or 1,25-dihydroxy vitamin D3, is being studied as a regulator of vitamin D receptor signaling across reproductive, immune, skeletal, and cancer biology. Recent in vitro evidence links this pathway to endometrial stromal-cell decidualization, while broader claims involving cytokines, Hedgehog signaling, and clinical outcomes remain context-dependent and require stronger primary-source support.

• Tacalcitol Sensitizes Colorectal Cancer to 5-FU

  2026-10-08

  Milczarek et al. identified a mechanistic basis for tacalcitol-mediated enhancement of 5-fluorouracil activity in HT-29 colorectal cancer cells: VDR-dependent induction of CDKN1A reduces thymidylate synthase at both the transcript and protein levels. The findings support a biomarker-oriented model involving VDR and CaSR, while remaining preclinical and limited to a defined cellular system.

• Perospirone: Receptor Selectivity Meets Vascular Kv1.5

  2026-10-08

  Perospirone (SM-9018 free base) combines high-affinity serotonergic and dopaminergic receptor activity with newly reported inhibition of vascular Kv currents. This evidence-focused analysis explains what the finding adds to schizophrenia research, cardiovascular pharmacology, and neuropsychiatric disorder models—while defining its translational limits.

• From Biotin-Free Labeling to Fluorescent Readouts

  2026-10-07

  The emerging BmTyr proximity-labeling platform shows how biotin-free chemistry can reduce endogenous biotin background in primary T-cell proteomics. This thought-leadership analysis explains why that advance complements, rather than displaces, Streptavidin-HyperFluor 647 for direct fluorescence-based detection of biotinylated targets.

• LIRP Enables Light-Controlled Gene Therapy

  2026-10-07

  The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that regulates therapeutic protein production at the translation stage. In mouse models, LIRP-based gene switches enabled light-responsive control of metabolic and retinal therapies, while also highlighting important translational limitations involving light delivery, vector biology, and clinical validation.

• Risedronate Sodium: Evidence and Research Context

  2026-10-06

  Risedronate Sodium is a nitrogen-containing bisphosphonate and FPP synthase inhibitor with an established mechanistic rationale for suppressing osteoclast-mediated bone resorption. The strongest supplied evidence concerns a 2023 formulation study of a dissolving microneedle patch containing risedronate and ursolic acid. Its findings support feasibility for transdermal delivery research, but not clinical efficacy. Claims involving emphysema, tumor cell lines, or broader repurposing remain preliminary because the supplied record lacks independently assessable clinical or full peer-reviewed evidence.

• Plant Protein Secretion: Methods, Scope, and Significance

  2026-10-06

  The second edition of Plant Protein Secretion: Methods and Protocols consolidates current approaches for studying conventional and unconventional protein secretion in plant cells. Its main contribution is methodological and organizational: it connects plant-specific endomembrane biology with reproducible experimental frameworks while highlighting questions that remain difficult to compare across systems.

• WAY-100635 in 5-HT1A Pain Research

  2026-10-05

  WAY-100635 is a selective, silent 5-HT1A receptor antagonist used in serotonin receptor antagonist research and receptor-imaging contexts. This overview places its pharmacological rationale alongside a 2026 mouse study of cannabidiol in orofacial inflammatory pain. The study reported sensory, affective, cognitive, endocannabinoid, inflammatory, and serotonergic changes, but it did not report using WAY-100635 or demonstrate that 5-HT1A receptors mediated cannabidiol’s effects. Accordingly, WAY-100635 is best framed as a hypothesis-testing tool for future neuroscience receptor pharmacology, not as evidence already established by the cannabidiol findings.

• CAR-M Immunotherapy in Hepatocellular Carcinoma

  2026-10-05

  A source-grounded overview of a 2026 preclinical study describing an in situ programmed CAR-macrophage approach for hepatocellular carcinoma. The analysis distinguishes reported findings from interpretation, compares evidence from mouse models and human organoids, and outlines translational limitations. It also clarifies that the listed APExBIO Anti-CD4 Antibody (Ibalizumab) was not evaluated in the cited study.

8663 records 1/578 page Next 12345 下5页 Last page